Antithymocyte globulin or interleukin 2 receptor antibody for immunosuppressive induction therapy after orthotopic liver transplantation: a follow-up study.
Keck
H
H
Department of Surgery, Virchow Clinic, Berlin, Germany.
Langrehr
J M
JM
Knoop
M
M
Lohmann
R
R
Neuhaus
P
P
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D015375:Receptors, Interleukin-2 / Q000276:immunology; D016019:Survival Analysis; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D015375:Receptors, Interleukin-2; C079843:inolimomab